RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewZacks Investment Research • 05/07/26
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewsWire • 05/06/26
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effectsReuters • 05/06/26
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewsWire • 05/06/26
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsInvestors Business Daily • 04/30/26
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewsWire • 04/29/26
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It SeemsThe Motley Fool • 04/27/26
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual MeetingGlobeNewsWire • 04/21/26
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual MeetingGlobeNewsWire • 04/21/26
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual MeetingGlobeNewsWire • 04/21/26
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual MeetingGlobeNewsWire • 04/19/26
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 04/17/26
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewsWire • 04/15/26
Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions UnderwaySeeking Alpha • 04/14/26
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer DataZacks Investment Research • 04/14/26
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior NotesGlobeNewsWire • 04/13/26
Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus ChemoBenzinga • 04/13/26